Introduction
Since androgen sensitivity of prostate cancer was demonstrated in 1941, 1 the mainstay of treatment for metastatic (M1) prostate cancer has been androgen deprivation, generally achieved by castration, either bilateral orchiectomy or maintenance luteinising hormone-releasing hormone (LHRH) agonist therapy. A major disadvantage associated with both methods of castration is the reduction in the levels of circulating testosterone originating from the testes. This can adversely affect patient quality of life, an important consideration in this palliative setting. In particular, libido and sexual potency are generally diminished 2, 3 and this may be unacceptable to some men. Additionally, some patients may have personal reasons for avoiding castration, may prefer oral therapy, or may not tolerate LHRH agonist therapy. There is, therefore, a need for alternative treatment options for these men.
Compounds that interfere with the production and/or function of androgens have been introduced for the management of advanced prostate cancer. The action of such antiandrogens results from the competitive inhibition of the binding of the metabolite of testosterone, dihydrotestosterone (DHT), to nuclear receptors in prostate cancer cells. 4 Steroidal antiandrogens have progestagenic properties and suppress gonadotrophins to lower plasma testosterone levels, and this also results in decreased libido and sexual potency. In contrast, nonsteroidal antiandrogens have no antigonadotrophic effects. As well as binding competitively to the prostatic intracellular androgen receptors, they also block androgen receptors in the brain, leading to successive increases in LHRH, luteinising hormone (LH) and testosterone secretion. By maintaining levels of circulating testosterone, non-steroidal antiandrogens have less of an impact on patients' libido and sexual potency. 5 As a result of increasing awareness of prostate cancer and advances in early detection, patients are being treated at an earlier stage of their disease. In the future, patients with metastatic prostate cancer will probably have less tumour burden and better performance status, and therefore will require treatment which has minimal impact on their quality of life.
This review discusses the possible role of the three nonsteroidal antiandrogens -bicalutamide ('Casodex', a trade mark of the AstraZeneca group of companies), flutamide and nilutamide -as alternatives to castration in patients with M1 prostate cancer. As well as examining the survival data, the benefits of non-steroidal antiandrogen monotherapy with respect to subjective response and quality of life are assessed. The tolerability profiles of the three compounds are also compared.
Survival data from non-steroidal antiandrogen studies in M1 patients Bicalutamide Bicalutamide is a potent, non-steroidal antiandrogen and has a half-life of approximately 1 week, which allows once daily dosing. 6 Two large, multicentre, randomised, Phase III studies of identical design compared bicalutamide 150 mg/day monotherapy with castration in men with locally advanced or advanced prostate cancer. 7, 8 A total of 480 patients with non-metastatic disease (M0) and 808 patients with confirmed metastatic disease (M1) were recruited.
A pooled analysis of the M1 patients was conducted at a median follow-up of 100 weeks. Survival data for M1 patients were considered mature at this point as 43% of M1 patients had died. The data showed that bicalutamide 150 mg/day was less effective than castration with respect to survival (hazard ratio (HR) 1.30; 95% confidence interval (CI) 1.04, 1.64; P ¼ 0.02). 7 However, the difference in estimated median survival times between the bicalutamide and castration groups was small (6 weeks (42 days)), see Figure 1 .
Flutamide
Flutamide is also a potent non-steroidal antiandrogen, but with lower affinity for the androgen receptor than bicalutamide. 9 It is rapidly and extensively metabolised, and the plasma half-life of its major metabolite (thought to be the active form of flutamide) is 5 -6 h. 10 Therefore, the parent drug must be administered three times daily.
Studies of flutamide monotherapy against active comparators in patients with M1 prostate cancer are summarised in Table 1 . Of these seven studies, 10 -16 only one compared flutamide monotherapy and castration. 14 Although no definite conclusions can be drawn from this small study (104 patients), overall survival at 69 months was identical in the two treatment groups. The other six studies compared flutamide monotherapy with other methods of androgen deprivation (Table 1) : maximal androgen blockade (MAB), 16 diethylstilboestrol (DES), 10 -13 and estramustine. 15 Five of the studies reported no statistically significant between-group differences in survival. 10 -12,14,16 In contrast, in the trial of 92 patients reported by Chang et al, 13 the DES treatment group had a significantly longer overall survival than flutamide-treated patients (43.2 vs 28.5 months; P ¼ 0.04), although median survival in the DES group was longer than normally expected in this setting. However, interpretation of the results of all these studies is difficult. The results of the largest study are only available in abstract form, 16 while all other studies lacked adequate statistical power. 
Nilutamide
Nilutamide is structurally similar to flutamide but has a longer half-life (approximately 2 days). 17 There are no comparative studies of nilutamide monotherapy vs castration in M1 patients. Published clinical experience with nilutamide monotherapy is limited to a single uncontrolled study of 26 previously untreated patients with metastatic prostate cancer. 18 The objective response rate to nilutamide 100 mg three times daily was approximately 40%, with a median progression-free survival and median overall survival of 9 and 23 months, respectively. However, because of the small sample size and lack of control group, it is impossible to draw any meaningful conclusions regarding the efficacy of nilutamide monotherapy.
Does disease volume affect the efficacy of antiandrogen therapy? Theoretical basis
There is a theoretical basis for antiandrogen efficacy being affected by tumour volume. Castration removes the major source of androgens from the body, irrespective of disease burden. In contrast, antiandrogens reduce exposure of prostate cancer cells to androgen by competing for the androgen receptor binding sites in the tumour cells. Therefore, the effectiveness of antiandrogens is partly dependent on the number of androgen receptor binding sites and, indirectly, on tumour burden. In addition, tumour volume will affect antiandrogen penetration. It follows that a dose of antiandrogen is likely to block androgen receptors more effectively in a patient with a low tumour burden than in a patient with a high tumour burden. Other factors, such as mutations in the androgen receptor gene, which occur more frequently in metastatic lesions than primary tumours, may also affect the binding and therefore the efficacy of antiandrogens in patients, particularly in patients with high-volume disease.
Circumstantial evidence from clinical studies
The possibility that the efficacy of antiandrogen monotherapy may be dependent on disease volume is suggested by the findings of the two large bicalutamide monotherapy studies. 7 In contrast to the M1 setting, M0 patients (after a median follow-up of 6.3 y with a death rate of 56%) demonstrated no statistically significant difference in overall survival between the bicalutamide 150 mg/day and castration groups (HR 1.05; 95% CI 0.81, 1.36; P ¼ 0.70). 8 In addition, in a small study of flutamide monotherapy, a post-hoc analysis of 28 evaluable M1 patients suggested flutamide monotherapy might offer a reasonable alternative to castration in patients with lowvolume disease. 14 However, the authors recommended that these results should be interpreted with extreme caution. In this study tumour burden was stratified on the basis of prostate specific antigen (PSA), since PSA concentrations in the serum correlate approximately with disease bulk. 19, 20 Prostatic disease burden has been reported to affect antiandrogen efficacy in MAB regimens. Two studies have reported benefits for MAB over castration in patients with minimal metastases but not those with extensive disease. 21, 22 However, a recent meta-analysis suggests the trend for efficacy in minimal disease is in favour of castration 23 and therefore this question has yet to be resolved.
Pre-treatment PSA values have also been found to be related to survival outcome in a study of 67 patients with metastatic prostate cancer treated with orchiectomy or flutamide plus goserelin ('Zoladex', a trade mark of the AstraZeneca group of companies). 24 A PSA level of 300 ng/ml could be used to discriminate between poor ( > 300 ng/ml) and better ( < 300 ng/ml) risk groups (P ¼ 0.003).
Evidence from studies of antiandrogen monotherapy
Based on PSA values, a post-hoc analysis of the two large bicalutamide monotherapy studies 7, 8 was conducted to establish whether there was a trend which related efficacy to the burden of the disease within the M1 patient population.
In this analysis, the M1 patients were divided into three groups of approximately equal size according to baseline levels of PSA: < 100 ng/ml (n ¼ 271), 100 -400 ng/ml (n ¼ 246) and > 400 ng/ml (n ¼ 260). As shown in Figure  2 , bicalutamide 150 mg/day and castration had similar efficacy in M1 patients with PSA 400 ng/ml (PSA < 100 ng/ml, HR 1.1; PSA 100 -400 ng/ml, HR 1.1). In contrast, the survival data favoured castration in M1 patients with baseline PSA > 400 ng/ml (HR 1.4). Similar data relating survival to disease burden are not available from the comparative flutamide monotherapy studies.
Effect of non-steroidal antiandrogens on subjective response and quality of life in M1 patients
Subjective response
In the two large bicalutamide monotherapy trials, a total of 288 M1 patients were symptomatic at study entry and therefore potentially able to exhibit a subjective response during the study. 7 Criteria for a subjective response were based on scores for performance status, cancer-related pain and requirements for cancer-related analgesia. Analysis revealed that the subjective response rate was significantly higher in the bicalutamide 150 mg/day group than in the castration group (70.0 vs 58.2%; P ¼ 0.046), see Figure 3 . 7 The odds ratio for this difference was 1.68, an odds ratio of > 1 indicating a greater chance of a subjective response being observed in M1 patients receiving bicalutamide.
Data on the subjective response to flutamide monotherapy is limited, but in their study comparing flutamide monotherapy and flutamide-based MAB, Pavone-Macaluso 16 reported that 66.2% of patients had a subjective response to flutamide monotherapy, a figure similar to that reported for bicalutamide 150 mg/day in the two large monotherapy studies but inferior to that for flutamide-based MAB (79.8%).
Quality of life
With increasing awareness of prostate cancer and advances in early detection, quality of life has become an important consideration in patients with advanced malignancy receiving palliative treatment. A comparative trial of 656 men with and without prostate cancer showed that a decline in sexual function was the most common cause of disease-specific stress, 25 and hence reduced quality of life. The impact of such factors can be considerable, with survey data showing that many men are willing to accept a treatment with higher mortality rates to avoid a 100% chance of impotence. 26, 27 In the two large trials of bicalutamide 150 mg/day monotherapy compared with castration, quality of life was assessed at 12 months by a questionnaire covering 10 quality of life dimensions (overall health, pain, emotional wellbeing, vitality, social function, physical capacity, sexual interest, sexual functioning, activity limitation and bed disability). 7 Very few patients with M1 disease answered the question on sexual function. When the results for M1 and M0 patients were combined, a non-significant trend towards less reduction of sexual function was seen in patients treated with bicalutamide compared with castration (20 vs 36%). In patients with M1 disease, statistically significant advantages were demonstrated in patients randomised to bicalutamide for physical capacity and sexual interest (P ¼ 0.032 and 0.041, respectively), see Figure 4 . 7 Only the quality of life domain 'overall health' favoured castration and this was not statistically significant.
Similarly, antiandrogen monotherapy (bicalutamide 150 mg/day) has been shown to confer quality of life advantages over MAB (goserelin plus flutamide) in a study involving a total of 220 patients (49.5% stage M0 and 50.5% stage M1 prostate cancer). 28 After a median follow-up of 38 months, significantly fewer patients receiving antiandrogen monotherapy complained of loss of sexual interest (P ¼ 0.01) and erectile dysfunction (P ¼ 0.002) than in the MAB group. There were also significant trends favouring antiandrogen monotherapy with respect to other quality of life parameters, ie social functioning, vitality, emotional wellbeing, and physical capacity.
There are no data on the comparative effects of flutamide monotherapy vs castration on sexual parameters, as the majority of the patients studied by Boccon-Gibod and colleagues 14 were impotent before study entry. Comparative data on other aspects of quality of life were not reported in any of the flutamide monotherapy studies.
Tolerability of non-steroidal antiandrogens
Antiandrogen monotherapy is generally well tolerated in men with metastatic prostate cancer, although differences in side effect profiles are apparent, which may influence the choice of antiandrogen.
In the two large-scale bicalutamide monotherapy studies, the events reported most frequently by the patients with M1 disease treated with bicalutamide 150 mg/day were breast pain and gynaecomastia. 7, 8 This was as expected because antiandrogens block receptors in a variety of testosterone-sensitive tissues, leaving unopposed oestrogen action in the breast. The incidence of hot flushes was lower in the bicalutamide group (9.5%) than in the castration group (38.6%). Otherwise the adverse event profiles for the two treatment groups were similar. The incidence of diarrhoea was low in both treatment arms (3.9 and 5.8% in the bicalutamidetreated patients from the two studies, respectively). Few M1 patients in the bicalutamide monotherapy group discontinued treatment due to drug-related adverse events (2.2%) (AstraZeneca, data on file). Bicalutamide was not associated with clinical hepatotoxicity in this study, although isolated cases of elevated liver enzymes were observed. 29 Cases of hepatic failure in bicalutamide- treated patients are rare. 30 Interstitial pneumonitis, an inflammatory condition of the lung, has also only been reported with bicalutamide therapy in isolated cases. 31 Gynaecomastia and breast pain are also the most common adverse events observed during flutamide monotherapy for advanced prostate cancer. 32 Gastrointestinal side effects, in particular diarrhoea, are also commonly associated with flutamide treatment, 33 -35 which can lead to treatment withdrawal. 32 Additionally, cases of clinical hepatotoxicity have been documented during flutamide therapy, 32,36 some of which have been fatal. 36 Nilutamide is associated with delayed adaptation to darkness after exposure to bright light, 37 -42 nausea and vomiting, 18,38 -40 and alcohol intolerance. 18, 39, 40, 43 These problems have not been associated with either bicalutamide or flutamide. In the small uncontrolled study reported by Decensi et al 18 decreased adaptation to darkness, nausea and alcohol intolerance were reported by 30.8, 26.9, and 19.2% of M1 patients, respectively. Interstitial pneumonitis has also been reported with nilutamide. 32, 39, 42, 44, 45 There are no direct comparisons between the nonsteroidal antiandrogens in the monotherapy setting. However, in the MAB setting, diarrhoea was found to be less frequent with bicalutamide therapy than with flutamide (12 vs 26%; P < 0.001). 46 Overall, withdrawal from therapy due to adverse events occurred for 10 and 16% of patients receiving bicalutamide and flutamide, respectively. Furthermore, there were fewer withdrawals due to diarrhoea in the bicalutamide group than in flutamide-treated patients (0.5 vs 6%). Treatment-related abnormal liver function test results were reported for 27 patients (7%) in the group receiving bicalutamide and 43 patients (11%) in the group receiving flutamide, but there were no reports of fatal hepatotoxicity in either group.
Conclusion
Of the three non-steroidal antiandrogens, only bicalutamide has been compared with castration in controlled, randomised, Phase III trials in M1 patients. Indeed, the majority of data on non-steroidal antiandrogen monotherapy in M1 prostate cancer originates from the combined results of two large-scale studies comparing bicalutamide 150 mg/day with castration. 7, 8 While flutamide has been compared with castration and other forms of androgen deprivation in Phase II and III studies, most studies had insufficient power to detect significant differences in survival outcome. There are no comparative data on nilutamide monotherapy.
A post-hoc analysis of M1 patients in the bicalutamide monotherapy studies, categorised by baseline PSA values, indicated that bicalutamide 150 mg/day monotherapy may be of particular benefit to M1 patients with a lower disease burden (PSA 400 ng/ml) for whom castration is not indicated or acceptable. Compared with castration, bicalutamide 150 mg/day monotherapy is associated with a small survival disadvantage in M1 patients with a higher disease burden (PSA > 400 ng/ml). However, because of quality of life advantages, these patients may still decide on antiandrogen monotherapy. The efficacy of second-line castration therapy following initial antiandrogen therapy has not been formally assessed. However, it is interesting to note that following progression in the M0 patients, some form of castration therapy was the commonest form of second-line therapy. Patients treated with bicalutamide tended to progress earlier than patients treated with castration; however, there was little difference between the treatment groups in terms of survival. This suggests that the development of a hormone-resistant state with initial antiandrogen therapy is unlikely to be a common problem, as patients still appear to respond to second-line castration therapy. Thus, initial bicalutamide monotherapy may be followed by castration on progression, with little risk of decreased efficacy being apparent.
Castration is the most widely used form of androgen ablation employed in the treatment of metastatic prostate cancer. Patients may have personal reasons for avoiding castration, may prefer an oral therapy or may not tolerate LHRH agonist therapy. Some men may also be willing to choose an alternative treatment with lower long-term survival in order to increase their chance of remaining sexually potent. 26 Non-steroidal antiandrogen monotherapy is a potential alternative treatment option to castration in these men. The decision on which treatment option to take should be made by the clinician in consultation with the patient.
